BeOne Medicines Plans $300M NJ Expansion, Bringing US Manufacturing Investment Over $1B
Editor’s Take: Whether based in the U.S. or globally, companies continue to seek opportunities to grow their business stateside.
BeOne Medicines is announcing a $300 million expansion of its clinical- and commercial-stage manufacturing and R&D center in Hopewell, NJ. This newest tranche of money takes BeOne’s United States manufacturing investment over $1 billion.
History of BeOne in NJ
The center, at the Princeton West Innovation Campus, opened in July 2024 on an initial investment of $800 million. A new, three-story, 145,000-square-foot building will bring the total campus footprint into the neighborhood of 545,000 square feet.
Over 42 acres, the site boasts more than 1 million square feet of developable real estate earmarked for future growth.
The expansion makes the campus a fully integrated, multi-platform manufacturing site combining existing biologics and new small molecule drug production.
Growing Manufacturing Capabilities
The added drug product manufacturing and packaging operations serve to strengthen BeOne’s production and supply chain capabilities. According to the company, this in turn supports a growing hematology portfolio and pipeline.
BeOne Medicines CEO Aaron Rosenberg weighed the impact of the announcement.
“[This] reflects BeOne’s commitment to strengthening U.S. manufacturing and expanding access to innovative medicines for patients with cancer,” Rosenberg said.
Not only President Donald Trump’s tax policies, Rosenberg said, but also NJ Governor Mikie Sherrill’s support of advanced manufacturing contributed.
In particular, the “Next New Jersey Manufacturing Program,” according to Rosenberg, encourages high-quality job creation.
“Together, these efforts create an environment for long-term growth,” Rosenberg said. “We are proud to continue expanding our global footprint in support of patients.”
The newly announced BeOne facility should be operational in 2029, the company says; subsequently, U.S. headcount will number approximately 240.
